Nose-to-Brain Delivery of Biopharmaceutics for the therapy of central nervous system diseases: A design-based approach for efficient drug delivery systems

Informazioni relative al progetto

Bio2Brain

ID dell’accordo di sovvenzione: 956977

DOI 10.3030/956977

Data della firma CE 18 Agosto 2020

Data di avvio 1 Gennaio 2021

Data di completamento 31 Dicembre 2024

Finanziato da

• EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions

Costo totale € 3 493 709,61

Contributo UE € 3 493 709,61

Coordinato da

FRAUNHOFER GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG EV
Germany

Risultati finali

Websites, patent fillings, videos etc. (6)

Semi-annual Newsletter M10

Semiannual Newsletter M10

Semi-annual Newsletter M27

Semiannual Newsletter M27

Bio2Brain Website
Semi-annual Newsletter M21

Semiannual Newsletter M21

Semi-annual Newsletter M15

Semiannual Newsletter M15

EAN conference

Other (1)

1st Summer School

Pubblicazioni

Peer reviewed articles (2)

Editorial: Intranasal Drug Delivery: Challenges and Opportunities

Autori: A. Fortuna, K. Schindowski, F. Sonvico
Pubblicato in: Frontiers in Pharmacology, 2022, ISSN 1663-9812
Editore: Frontiers Media S.A.
DOI: 10.3389/fphar.2022.868986

Fc-Engineered Therapeutic Antibodies: Recent Advances and Future Directions

Autori: D. T. Abdeldaim, K. Schindowski
Pubblicato in: Pharmaceutics, 2023, ISSN 1999-4923
Editore: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/pharmaceutics15102402